心力健丸治療心肺氣虛、血瘀水停型慢性心衰的臨床觀察
發(fā)布時(shí)間：2018-12-16 16:50
【摘要】：目的:本次臨床觀察是通過運(yùn)用心力健丸聯(lián)合西藥治療心肺氣虛、血瘀水停型慢性心力衰竭患者并觀察其治療效果,從理論方面探索和分析作用機(jī)制為慢性心力衰竭的治療提供新的中成藥制劑,從而拓寬慢性心力衰竭的治療方法,便于實(shí)際運(yùn)用。方法:選擇武漢市黃陂區(qū)中醫(yī)院心血管科2015年12月-2016年12月中心肺氣虛、血瘀水停型慢性心衰住院患者60例,年齡為50-75歲區(qū)間內(nèi),心功能處于II-III級(jí)(NYHA分級(jí))。將60例患者隨機(jī)分為治療組30例和對(duì)照組30例,治療組口服心力健丸與西藥治療,對(duì)照組按常規(guī)西藥治療。心力健丸為我院研發(fā)制劑,由本院煎藥室制成水丸,服藥療程為3個(gè)月,服用方法為每日3次,每次15粒。分別于治療前后觀察中醫(yī)癥狀積分、NYHA心功能分級(jí)、Lee氏心衰療效積分、LVEF、NT-pro BNP的水平、血液生化指標(biāo)。結(jié)果:經(jīng)過3個(gè)月的治療,兩組患者都取得了良好的治療效果,臨床癥狀積分的結(jié)果顯示治療后兩組患者的中醫(yī)證侯積分及Lee氏評(píng)分(P0.05)均有所降低,治療組療效優(yōu)于對(duì)照組;治療后兩組NYHA心功能分級(jí)(P0.05)均得以改善,且治療組改善更為明顯(P0.05);在NTpro-BNP方面治療后降低了兩組NTpro-BNP水平(P0.01),且治療組較對(duì)照組NTpro-BNP下降的更明顯;兩組患者治療后左室射血分?jǐn)?shù)(LVEF)均得以提高,且治療組提高更為明顯(P0.05)。所有患者服藥依從性較高,在治療過程中未因出現(xiàn)嚴(yán)重不良反應(yīng)而中斷治療,血液生化檢查均處于正常范圍內(nèi)。結(jié)論:通過本次臨床觀察可以看出心力健丸治療心肺氣虛、血瘀水停型慢性心力衰竭可明顯降低中醫(yī)癥狀積分與Lee氏心衰療效積分,改善患者心衰的癥狀,降低全血NT-pro BNP水平,改善機(jī)體鈉水儲(chǔ)留,減輕心臟負(fù)荷,提高慢性心力衰竭患者心功能水平。治療過程中無明顯毒副作用。配合西藥常規(guī)治療,標(biāo)本兼治,在臨床上療效取得良好的效果。
[Abstract]:Objective: this clinical observation is to use Xinlijian pills combined with western medicine to treat patients with chronic heart failure with deficiency of heart and lung qi, blood stasis and water stasis, and observe its therapeutic effect. To explore and analyze the mechanism of action in theory, to provide a new Chinese patent medicine for the treatment of chronic heart failure, so as to broaden the treatment method of chronic heart failure and facilitate its practical application. Methods: from December 2015 to December 2016, 60 patients with chronic heart failure (CHF) with central lung qi deficiency and blood stasis and water stagnation were selected from Department of Cardiology, Huangpi District traditional Chinese Medicine Hospital, Wuhan City. Their heart function was in II-III grade (NYHA grade). 60 patients were randomly divided into treatment group (n = 30) and control group (n = 30). Xinlijian Pill is a research and development preparation in our hospital. It is made into water pill by the decoction room of our hospital. The course of treatment is 3 months, and the method is taken 3 times a day, 15 capsules per time. Before and after treatment, TCM symptom score, NYHA cardiac function grade, Lee's heart failure curative effect score, LVEF,NT-pro BNP level and blood biochemical index were observed. Results: after 3 months of treatment, both groups achieved good therapeutic effect. The results of clinical symptom score showed that the TCM syndromes score and Lee's score (P0.05) of the two groups decreased after treatment. The curative effect of the treatment group was better than that of the control group. After treatment, the NYHA cardiac function grading (P0.05) was improved in both groups, and the improvement was more obvious in the treatment group (P0.05). After NTpro-BNP treatment, the level of NTpro-BNP was decreased in both groups (P0.01), and the decrease of NTpro-BNP in the treatment group was more obvious than that in the control group. Left ventricular ejection fraction (LVEF) was significantly increased in both groups (P0.05). All the patients had high compliance, no serious adverse reactions occurred during the treatment, and the blood biochemical examination was within the normal range. Conclusion: through this clinical observation, it can be seen that Xinlijian Pill can significantly reduce the scores of TCM symptoms and the curative effect of Lee's Heart failure in treating chronic heart failure with deficiency of heart and lung qi, blood stasis and water stagnation, and improve the symptoms of heart failure in patients. The level of NT-pro BNP in whole blood was decreased, the retention of sodium and water was improved, the cardiac load was alleviated, and the cardiac function was improved in patients with chronic heart failure. There were no obvious side effects during the treatment. In combination with routine treatment of western medicine, both symptoms and symptoms have been treated, and good results have been achieved in clinical treatment.
【學(xué)位授予單位】：湖北中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259
[Abstract]:Objective: this clinical observation is to use Xinlijian pills combined with western medicine to treat patients with chronic heart failure with deficiency of heart and lung qi, blood stasis and water stasis, and observe its therapeutic effect. To explore and analyze the mechanism of action in theory, to provide a new Chinese patent medicine for the treatment of chronic heart failure, so as to broaden the treatment method of chronic heart failure and facilitate its practical application. Methods: from December 2015 to December 2016, 60 patients with chronic heart failure (CHF) with central lung qi deficiency and blood stasis and water stagnation were selected from Department of Cardiology, Huangpi District traditional Chinese Medicine Hospital, Wuhan City. Their heart function was in II-III grade (NYHA grade). 60 patients were randomly divided into treatment group (n = 30) and control group (n = 30). Xinlijian Pill is a research and development preparation in our hospital. It is made into water pill by the decoction room of our hospital. The course of treatment is 3 months, and the method is taken 3 times a day, 15 capsules per time. Before and after treatment, TCM symptom score, NYHA cardiac function grade, Lee's heart failure curative effect score, LVEF,NT-pro BNP level and blood biochemical index were observed. Results: after 3 months of treatment, both groups achieved good therapeutic effect. The results of clinical symptom score showed that the TCM syndromes score and Lee's score (P0.05) of the two groups decreased after treatment. The curative effect of the treatment group was better than that of the control group. After treatment, the NYHA cardiac function grading (P0.05) was improved in both groups, and the improvement was more obvious in the treatment group (P0.05). After NTpro-BNP treatment, the level of NTpro-BNP was decreased in both groups (P0.01), and the decrease of NTpro-BNP in the treatment group was more obvious than that in the control group. Left ventricular ejection fraction (LVEF) was significantly increased in both groups (P0.05). All the patients had high compliance, no serious adverse reactions occurred during the treatment, and the blood biochemical examination was within the normal range. Conclusion: through this clinical observation, it can be seen that Xinlijian Pill can significantly reduce the scores of TCM symptoms and the curative effect of Lee's Heart failure in treating chronic heart failure with deficiency of heart and lung qi, blood stasis and water stagnation, and improve the symptoms of heart failure in patients. The level of NT-pro BNP in whole blood was decreased, the retention of sodium and water was improved, the cardiac load was alleviated, and the cardiac function was improved in patients with chronic heart failure. There were no obvious side effects during the treatment. In combination with routine treatment of western medicine, both symptoms and symptoms have been treated, and good results have been achieved in clinical treatment.
【學(xué)位授予單位】：湖北中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 閆秋林;毛以林;;毛以林辨證論治慢性心衰經(jīng)驗(yàn)[J];世界中西醫(yī)結(jié)合雜志;2016年04期
2 王U，
本文編號(hào)：2382721
本文鏈接：http://sikaile.net/zhongyixuelunwen/2382721.html
最近更新
教材專著
